The study of the efficacy of late intensification therapy and biochemical markers for pediatric Langerhans cell histiocytosis (JLSG-02)
Phase 2
- Conditions
- angerhans cell histiocytosis
- Registration Number
- JPRN-UMIN000018426
- Lead Sponsor
- Japan LCH Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with organ failure which make difficult to carry out the treatment 2. Patients receiving other treatment except steroids or surgical treatment for LCH 3. Informed consent is not obtained from patients and / or the guardians for treatment JLSG-02
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Event free survival at 5 years.
- Secondary Outcome Measures
Name Time Method Overall survival at 5 years.